European Journal of Radiology Open (Jan 2018)

Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score

  • Rajeev Jyoti,
  • Tarun Pankaj Jain,
  • Hodo Haxhimolla,
  • Heath Liddell,
  • Sean Edward Barrett

Journal volume & issue
Vol. 5
pp. 58 – 63

Abstract

Read online

Introduction: The purpose was to investigate the usefulness of ADCratio on Diffusion MRI to discriminate between benign and malignant lesions of Prostate. Methods: Images of patients who underwent in-gantry MRI guided prostate lesion biopsy were retrospectively analyzed. Prostate Cancers with 20% or more Gleason score (GS) pattern 3 + 3 = 6 in each core or any volume of higher Gleason score pattern were included. ADCratio was calculated by two reviewers for each lesion. The ADCratio was calculated for each lesion by dividing the lowest ADC value in a lesion and highest ADC value in normal prostate in peripheral zone (PZ). ADCratio values were compared with the biopsy result. Data was analysed using independent samples T-test, Spearman correlation, intra-class correlation coefficient (ICC) and Receiver operating characteristic (ROC) curve. Results: 45 lesions in 33 patients were analyzed. 12 lesions were in transitional zone (TZ) and 33 in perpheral zone PZ. All lesions demonstrated an ADCratio of 0.45 or lower. GS demonstrated a negative correlation with both the ADC value and ADCratio. However, ADCratio (p < 0.001) demonstrated a stronger correlation compared to ADC value alone (p = 0.014). There was no significant statistical difference between GS 3 + 4 and GS 4 + 3 mean ADCtumour value (p = 0.167). However when using ADCratio, there was a significant difference (p = 0.032). ROC curve analysis demonstrated an area under the curve of 0.83 using ADCratio and 0.76 when using ADCtumour value when discriminating Gleason 6 from Gleason ≥7 tumours. Inter-observer reliability in the calculation of ADC ratios was excellent, with ICC of 0.964. Conclusion: ADCratio is a reliable and reproducible tool in quantification of diffusion restriction for clinically significant prostate cancer foci. Keywords: Prostate, Prostatic cancer, Magnetic resonance imaging, Diffusion magnetic resonance imaging, Prostatic neoplasms